Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study.
Forty postmenopausal women, referred for hormone replacement therapy and all of whom reported a significant concern about a decline in their sexual interest, were randomly allocated to one of two hormone implant treatment groups: either oestradiol (50 mg) alone, or oestradiol (50 mg) and testosterone (100 mg). Comparison between the two groups as a whole revealed no significant differences on any measure, both treatments being associated with a significant reduction in the severity of psychological, somatic and vasomotor symptoms, and with a significant improvement in sexual interest and responsiveness. Similar effects were also observed in patients who denied, pretreatment, any concurrent dyspareunia. Although it is not possible to identify the reasons for change, the results indicate no advantages of supplementary testosterone administration over oestradiol alone for sexually unresponsive postmenopausal women.
D000328:Adult; D004343:Drug Implants; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007989:Libido / Q000187:drug effects; D008297:Male; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*; D013739:Testosterone / Q000627:therapeutic use*
D004343:Drug Implants; D013739:Testosterone; D004958:Estradiol